Compare RBKB & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | RBKB | ACOG |
|---|---|---|
| Founded | 1860 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 200.9M | 193.6M |
| IPO Year | 2018 | 2024 |
| Metric | RBKB | ACOG |
|---|---|---|
| Price | $12.89 | $8.23 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 63.1K | ★ 94.5K |
| Earning Date | 11-03-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 215.00 | 41.58 |
| EPS | ★ 0.44 | N/A |
| Revenue | $2,984,000.00 | ★ $10,220,275.00 |
| Revenue This Year | N/A | $153.87 |
| Revenue Next Year | N/A | $85.66 |
| P/E Ratio | $29.43 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.41 | $4.50 |
| 52 Week High | $17.99 | $10.14 |
| Indicator | RBKB | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 51.30 | 40.60 |
| Support Level | $12.58 | $8.30 |
| Resistance Level | $13.00 | $9.48 |
| Average True Range (ATR) | 0.18 | 0.43 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 45.93 | 23.64 |
Rhinebeck Bancorp Inc is the holding company for Rhinebeck Bank, which is a New York-chartered stock savings bank. It provides a full range of banking and financial services to consumer and commercial customers. Financial services, including investment advisory and financial product sales, are offered through a division of the Bank doing business as Rhinebeck Asset Management. The Bank's primary business activity is accepting deposits from the general public and using those funds together with borrowings, to originate commercial real estate loans (which include multi-family real estate loans and commercial construction loans), commercial business loans and indirect automobile loans, and to purchase one- to four-family residential real estate loans and investment securities.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.